Evidence map›Paper›PMID 38250076›Full record

ArticleFrontiers in immunology2023

Clinicopathological and prognostic characteristics of idiopathic membranous nephropathy with dual antigen positivity.

Lei Yang, Guoqin Wang, Nan Ye, Xiaoyi Xu, Wenrong Cheng, Lijun Sun, Hongrui Dong, Lingqiang Kong, Xiaoyi Zhao, Yanqiu Geng and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. NELL-1: role and mechanisms in disease pathogenesis and development.Frontiers in cell and developmental biology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Lei YangBeijing Anzhen Hospital, Capital Medical University, Beijing, China.
Guoqin WangBeijing Anzhen Hospital, Capital Medical University, Beijing, China.
Nan YeBeijing Anzhen Hospital, Capital Medical University, Beijing, China.
Xiaoyi XuBeijing Anzhen Hospital, Capital Medical University, Beijing, China.
Wenrong ChengBeijing Anzhen Hospital, Capital Medical University, Beijing, China.
Lijun SunBeijing Anzhen Hospital, Capital Medical University, Beijing, China.
Hongrui DongBeijing Anzhen Hospital, Capital Medical University, Beijing, China.
Lingqiang KongBeijing Anzhen Hospital, Capital Medical University, Beijing, China.
Xiaoyi ZhaoDivision of Nephrology, Affiliated Hospital of Chifeng University, Neimenggu, China.
Yanqiu GengDivision of Nephrology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.
Hong ChengBeijing Anzhen Hospital, Capital Medical University, Beijing, China.
Capital Medical University · CNBeijing Anzhen Hospital · CNChifeng University · CNChinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Idiopathic membranous nephropathy (IMN) is the most common pathological type in adults with nephrotic syndrome. Many target antigens have been discovered. However, dual antigen-positive IMN patients are very rare, with only a few such cases being briefly described in various studies. There is no specific study on the clinicopathological and prognostic characteristics of dual antigen-positive IMN patients, and the disease characteristics of such patients remain unclear. Methods: Immunohistochemical staining of PLA2R, THSD7A, and NELL-1 was conducted on kidney tissue samples obtained from patients diagnosed with IMN. Simultaneously, the presence of corresponding serum antibodies was determined. Patients exhibiting positivity for dual antigens were included in the study, identified either through tissue staining or serum antibody detection. We retrospectively collected their clinical, pathological, and follow-up data and measured their serum antibody levels at multiple time points. Additionally, the same type of dual antigen-positive IMN cases reported in the literature were reviewed to extract clinical, pathological, and prognostic information. We compared the data for all of the above dual antigen-positive and PLA2R single-positive IMN cases at our center. Results: We identified 6 IMN patients with dual antigen positivity at our center, approximately 0.7% of whole MN series; the previous literature reports 43 IMN patients with dual antigen positivity, the proportion ranged from 0.2% to 2.8%. The IgG1 positivity rate in the renal tissue of the dual antigen-positive patients at our center was significantly lower than that of dual antigen-positive patients previously reported (16.7% vs. 100.0%, p=0.015), but there was no significant difference in clinical or prognostic aspects. Patients with dual antigen positivity reported at our center and in the literature were combined and compared with PLA2R single-positive IMN reported at our center. Compared with PLA2R single-positive IMN patients, dual antigen-positive IMN patients had a higher renal tissue IgG1 positivity rate (58.3% vs. 22.3%, p=0.016), and the time required to achieve remission was longer [13.5 (3.3,35.0) vs. 3.0 (1.0,8.0), p=0.052]. Overall, The changes in urine protein were consistent with the changes in serum PLA2R antibody levels in dual antigen-positive IMN patients. Conclusions: For patients with primary membranous nephropathy who did not attain remission following prolonged treatment, multiple target antigen staining should still be actively performed, even with positivity for the PLA2R target antigen.

Indexed as

Glomerulonephritis, MembranousNephrotic SyndromeAdultHumansImmunoglobulin GPrognosisRetrospective StudiesImmunoglobulin Gdual antigenidiopathic membranous nephropathyNELL-1PLA2RTHSD7A

Identifiers

PMID38250076
PMCPMC10796489
OpenAlexW4390610570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.